PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
16.52%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
16.61%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
17.14%
EPS growth of 17.14% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
17.14%
Diluted EPS growth of 17.14% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reduction while CRVO stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
9.84%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
13.18%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Negative 10Y OCF/share CAGR while CRVO stands at 99.95%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
90.48%
5Y OCF/share CAGR is similar to CRVO's 99.10%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
83.42%
3Y OCF/share CAGR at 75-90% of CRVO's 94.63%. Bill Ackman would press for improvements in margin or overhead to catch up.
-2587.91%
Negative 10Y net income/share CAGR while CRVO is at 99.99%. Joel Greenblatt sees a major red flag in long-term profit erosion.
90.30%
5Y net income/share CAGR similar to CRVO's 99.40%. Walter Schloss might see both on parallel mid-term trajectories.
86.48%
3Y net income/share CAGR similar to CRVO's 95.22%. Walter Schloss would attribute it to shared growth factors or demand patterns.
1551.35%
10Y equity/share CAGR above 1.5x CRVO's 100.38%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-71.69%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-47.82%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth well under 50% of CRVO's 102.72%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
15.36%
BV/share growth of 15.36% while CRVO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
-14.09%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-7.82%
Our R&D shrinks while CRVO invests at 12.93%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.34%
We cut SG&A while CRVO invests at 17.83%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.